Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
940 participants
INTERVENTIONAL
2016-11-30
2023-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Hypertension treatment within the UK is currently selected according to age and self-defined ethnicity (SDE). There are limitations to this approach which include wide variability in the response to hypertension drug classes between people. There is also uncertainty about selecting hypertension drugs for ethnic minorities other than those of African/Caribbean ancestry, for example, South Asians because of a lack of information from trials. In the AIM HY-INFORM study the investigators are looking to recruit equal number of black/caribbean, south asian and white european participants to be able to compare differences in hypertension treatments and ethnicity.
The primary objective of this study is to determine if the response to antihypertensive drugs differs by self defined ethnicity.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients
NCT01011660
Blood Pressure and Lipids Reduction in High Risk Elderly Patients With Isolated Systolic Hypertension
NCT05165251
Open Label Study Telmisartan and Amlodipine in Hypertension
NCT00614380
Efficacy of Chlorthalidone and Hydrochlorothiazide Combined With Amiloride on Blood Pressure in Primary Hypertension.
NCT03928145
S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension
NCT03226340
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Stratification based on SDE has a number of limitations and an alternative approach is stratification based on ancestry informative markers (AIM). There are genetic polymorphisms, which show substantially different frequencies between populations from different geographical regions, and can predict geographical ancestry with remarkable accuracy. AIM are thus more likely to capture the genetic component of variation in drug response in ethnically diverse population.
Metabolomic profiling of plasma and urine may provide complementary information to AIM, as differences between individuals will reflect both genetic and environmental influences. To address these issues the investigators intend to compare the variation in response to antihypertensive drug treatments in three SDE cohorts, and relate this to variation in AIM and metabolomic profiles. Our objective is to test the validity of current NICE guidance on antihypertensives stratification based on SDE, to provide evidence about SDE stratification for dual therapy, and to examine whether more effective personalisation of antihypertensive treatment, can be achieved using AIM and/or metabolomic profiling.
An assessment of patient stratification based on AIM phenotypes against SDE will enable the selection of optimal and more effective choices of anti-hypertensive treatments from currently existing first line drugs (and combinations of) and ultimately reduce the attrition of antihypertensive therapies.
Output from the trial will provide the first perspective evidence for best treatment choice according to SDE for white, black and asian populations in the UK. This should reduce the number of consultations; time required to achieve optimal blood pressure control and the contribution to between hypertension control in the UK.
Patients in the trial will be enrolled on a monotherapy or dual therapy regime depending on their history of hypertension. The monotherapy group of patients will enter a randomised, open-label, three-treatment three-period cross over trial.
The dual therapy group of patients will enter a randomised, open-label, four-treatment four-period cross over trial.
Randomisation, for each crossover design, will be stratified by three SDE groups.
The duration for individual participants will be approximately 24 (monotherapy) or 32 weeks (dual therapy)
The hypertensive medication used in this trial are:
Amlodipine 5 or 10mg, Chlortalidone 25mg, Amiloride 10mg, Lisinopril 10 or 20mg,
Participants on the dual therapy treatment arm will have a total of 11 visits including screening/enrolment (visit 1) and baseline visit (visit 2)
Participants on the monotherapy treatment arm will have a total of 9 visits including screening/enrolment (visit 1) and baseline visit (visit 2)
A total number of 1320 participants will be enrolled in the study across participating sites, so that approximately 660 participants in each therapy regime (approximately 220 participants per ethnic group) complete the trial.
An optional skin-sodium investigation will be conducted at selected sites only where capacity and capability to complete the sub study investigations is demonstrated. The sub study aims to recruit up to 60 participants who have already given consent for the main AIM HY INFORM Trial. Consent for the optional sub-study will be obtained separately.
The investigation comprises two optional assessments: a skin biopsy and a sodium magnetic resonance imaging (23Na MRI) scan. Both assessments will be used to quantify skin sodium levels. Participants in the mono and dual therapy arms can elect to have the skin biopsy, the MRI scan, or both, at the baseline visit. Participants in the mono therapy arm only, can elect to have the skin biopsy, the MRI scan, or both, following completion of the amlodipine (A) and chlortalidone (C) study arms. The additional measurements are not anticipated to take more than approximately 2 hours.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mono-therapy group
The monotherapy group will be treated with the following treatments:
A) 1 to 2 weeks of Amlodipine 5mg followed by 6 to 7 weeks of Amlodipine 10mg B) 1 to 2 weeks of Lisinopril 10mg followed by 6 to 7 weeks of Lisinopril 20mg C) Approximately 8 weeks of 25mg Chlortalidone
Participants will be randomly allocated to one of six possible sequences of treatments of the three-treatment-three period Williams design: ABC, ACB, BAC, BCA, CAB, and CBA.
Amlodipine
Amlodipine 5mg and Amlodipine 10mg will be one of the treatments in which patients will receive on the monotherapy arm and on the dual therapy arm.
Lisinopril
Lisinopril 10mg and Lisinopril 20mg will be one of the treatments in which patients will receive on the monotherapy arm.
Lisinopril 20mg will be one of the treatments in which patients will receive on the dual therapy arm.
Chlortalidone
Chlortalidone 25mg will be one of the treatments in which patients will receive on the dual therapy arm and monotherapy arm.
Dual-therapy arm
The dual-therapy group will be treated with the following treatments:
A) Approximately 8 weeks of Amlodipine 5mg and Lisinopril 20mg B) Approximately 8 weeks of Amlodipine 5mg and Chlortalidone 25mg C) Approximately 8 weeks of Lisinopril 20mg and Chlortalidone 25mg D) Approximately 8 weeks of Amiloride 10mg and Chlortalidone 25mg
Participants will be randomly allocated to one of four possible sequences of treatments of the four-treatment four-period Williams design: ABDC, BCAD, CDBA, and DACB.
Amlodipine
Amlodipine 5mg and Amlodipine 10mg will be one of the treatments in which patients will receive on the monotherapy arm and on the dual therapy arm.
Lisinopril
Lisinopril 10mg and Lisinopril 20mg will be one of the treatments in which patients will receive on the monotherapy arm.
Lisinopril 20mg will be one of the treatments in which patients will receive on the dual therapy arm.
Amiloride
Amiloride 10mg will be one of the treatments in which patients will receive on the dual therapy arm.
Chlortalidone
Chlortalidone 25mg will be one of the treatments in which patients will receive on the dual therapy arm and monotherapy arm.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Amlodipine
Amlodipine 5mg and Amlodipine 10mg will be one of the treatments in which patients will receive on the monotherapy arm and on the dual therapy arm.
Lisinopril
Lisinopril 10mg and Lisinopril 20mg will be one of the treatments in which patients will receive on the monotherapy arm.
Lisinopril 20mg will be one of the treatments in which patients will receive on the dual therapy arm.
Amiloride
Amiloride 10mg will be one of the treatments in which patients will receive on the dual therapy arm.
Chlortalidone
Chlortalidone 25mg will be one of the treatments in which patients will receive on the dual therapy arm and monotherapy arm.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Have given written informed consent to participate
2. Be aged 18 to 65 years inclusive
3. Self-Define Ethnicity: participants should SELF IDENTIFY into 1 of the three groups below:
White White British White Irish Any other white background
Black or Black British Black Caribbean Black African Any other black background
Asian or Asian British Asian Indian Asian Pakistani Asian Bangladeshi Any other Asian background
4. Be hypertensive defined as:- Mono-therapy rotation
1. currently untreated with EITHER an ABPM day time average blood pressure ≥ 135mmHG (systolic) or ≥ 85mmHg (diastolic) OR Home BP measurements using a validated device based on the average of 10 blood pressure readings of ≥135 mmHg (systolic) or ≥85 mmHg (diastolic)
2. Patients who may be taking antihypertensive drugs at sub therapeutic doses or in ineffective combinations, and who are felt likely to be controllable on a study drug and willing and able to be washed out, at the discretion of the CI (Chief Investigator) / PI (Principal Investigator), can enter the trial if they meet the above criteria.
Dual therapy rotation
a.Treated hypertensive receiving one to three antihypertensive drugs with a blood pressure (ABPM daytime average blood pressure or Home BP as in a.) between 135 or 200 mmHg (systolic) AND between 85 or 110 mmHg (diastolic).
Exclusion Criteria
* Participant does not fit into one of the defined ethnic groups e.g. Mixed
* Pregnant or breastfeeding women
* Known or suspected secondary hypertension
* Significant sensitivity or contraindications to any of the study medications
* Participants taking lithium or are regularly consuming non-steroidal anti-inflammatory drugs at variable doses
* Requirement to take any of the study drugs continuously e.g. ACEi and heart failure
* Any clinically significant hepatic impairment
* Any clinically significant kidney impairment
* Concurrent participation in another clinical trial using systemic vasoactive medications or medications known to interact with the study drugs (participation in another study as part of the AIM HY mechanistic or social science programme will not be an exclusion criterion)
* Patients who are deemed unsuitable by the investigator on clinical grounds
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical Research Council
OTHER_GOV
Cambridge University Hospitals NHS Foundation Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Ian B Wilkinson
Consultant
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ian Wilkinson
Role: PRINCIPAL_INVESTIGATOR
Cambridge University Hospitals NHS Foundation Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cambridge University Hospitals NHS Foundation Trust
Cambridge, Cambridgeshire, United Kingdom
Queen Elizabeth Hospital
Birmingham, , United Kingdom
Sandwell & West Birmingham Hospitals NHS Trust
Birmingham, , United Kingdom
Heartlands Hospital
Birmingham, , United Kingdom
University Hospital Llandough
Cardiff, , United Kingdom
University of Glasgow
Glasgow, , United Kingdom
Liverpool Heart and Chest Hospital
Liverpool, , United Kingdom
William Harvey Research Institute, Barts and the London Medical School
London, , United Kingdom
St Thomas' Hospital
London, , United Kingdom
St George's Hospital
London, , United Kingdom
Hammersmith & Fulham GP Partnership: Richford Gate Medical Practice
London, , United Kingdom
Manchester Royal Infirmary
Manchester, , United Kingdom
Nottingham University Hospital: QMC Campus
Nottingham, , United Kingdom
Lister Hospital
Stevenage, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wych J, Grayling MJ, Mander AP. Sample size re-estimation in crossover trials: application to the AIM HY-INFORM study. Trials. 2019 Dec 2;20(1):665. doi: 10.1186/s13063-019-3724-6.
Mukhtar O, Cheriyan J, Cockcroft JR, Collier D, Coulson JM, Dasgupta I, Faconti L, Glover M, Heagerty AM, Khong TK, Lip GYH, Mander AP, Marchong MN, Martin U, McDonnell BJ, McEniery CM, Padmanabhan S, Saxena M, Sever PJ, Shiel JI, Wych J, Chowienczyk PJ, Wilkinson IB. A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program-AIM-HY INFORM trial. Am Heart J. 2018 Oct;204:102-108. doi: 10.1016/j.ahj.2018.05.006. Epub 2018 May 20.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AO94005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.